Ankylosing Spondylitis (Bekhterevs Disease) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 119 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2014', provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ankylosing Spondylitis (Bekhterev's Disease) Overview 9
Therapeutics Development 10
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 10
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis 11
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 12
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 18
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 19
Boehringer Ingelheim GmbH 19
Piramal Enterprises Limited 20
Celltrion, Inc. 21
Novartis AG 22
Biocon Limited 23
Pfizer Inc. 24
Sandoz Inc. 25
Celgene Corporation 26
Lupin Limited 27
Panacea Biotec Limited 28
Avesthagen Limited 29
Covagen AG 30
Biosidus S.A. 31
Inbiopro Solutions Pvt. Ltd. 32
Innovent Biologics, Inc. 33
Epirus Biopharmaceuticals, Inc. 34
AlphaMab Co., Ltd 35
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
infliximab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
apremilast - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
secukinumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
etanercept biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
adalimumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
tofacitinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BI-655066 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
infliximab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
COVA-322 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
adalimumab biosimilar - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
etanercept biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
P-979 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
etanercept biosimilar - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
adalimumab biosimilar - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
etanercept biosimilar - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
IBPM-005IX - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
IBPM-004AM - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
etanercept biosimilar - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
etanercept biosimilar - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
adalimumab biosimilar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
adalimumab biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
adalimumab biosimilar - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
INV-17 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
etanercept biosimilar - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
IBI-303 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ND-007 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
adalimumab biosimilar - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
etanercept biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates 82
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 106
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 107
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 108
Featured News & Press Releases 108
Jul 09, 2014: Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis 108
Apr 10, 2014: Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS (Prednisone) Delayed-Release Tablets 109
Oct 18, 2013: Cimzia Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis 110
Sep 11, 2013: Hospira's Inflectra the first biosimilar monoclonal antibody to be approved in Europe 111
Sep 05, 2013: Horizon Pharma Announces Sanofi Compiegne as Additional Manufacturing Site for DUEXIS 113
Aug 22, 2013: Horizon Pharma Announces Settlement of DUEXIS Patent Litigation With Par Pharmaceutical 113
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 114
Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima 115
May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process 117
Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 119
Disclaimer 119

List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2014 10
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 19
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Piramal Enterprises Limited, H2 2014 20
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H2 2014 21
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2014 22
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H2 2014 23
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H2 2014 24
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz Inc., H2 2014 25
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H2 2014 26
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Limited, H2 2014 27
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H2 2014 28
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H2 2014 29
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Covagen AG., H2 2014 30
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biosidus S.A., H2 2014 31
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 32
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H2 2014 33
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 34
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AlphaMab Co., Ltd, H2 2014 35
Assessment by Monotherapy Products, H2 2014 36
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H2 2014 82
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2014 106
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2014 107